Therasense Stock Cash Flow From Operations
| THER Stock | USD 0.0001 0.00 0.00% |
Therasense fundamentals help investors to digest information that contributes to Therasense's financial success or failures. It also enables traders to predict the movement of Therasense Pink Sheet. The fundamental analysis module provides a way to measure Therasense's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Therasense pink sheet.
Therasense |
Therasense Company Cash Flow From Operations Analysis
Therasense's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Therasense Cash Flow From Operations | (5.54 M) |
Most of Therasense's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Therasense is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Therasense has (5.54 Million) in Cash Flow From Operations. This is 101.05% lower than that of the Healthcare sector and 108.86% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.57% higher than that of the company.
Therasense Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Therasense's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Therasense could also be used in its relative valuation, which is a method of valuing Therasense by comparing valuation metrics of similar companies.Therasense is currently under evaluation in cash flow from operations category among its peers.
Therasense Fundamentals
| Return On Asset | -169.9 | |||
| Current Valuation | 27.3 M | |||
| Shares Outstanding | 6.15 B | |||
| Shares Owned By Insiders | 83.61 % | |||
| Number Of Shares Shorted | 199.92 K | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 57.46 X | |||
| Revenue | 353.26 K | |||
| Gross Profit | 256.68 K | |||
| EBITDA | (5.53 M) | |||
| Net Income | (7.75 M) | |||
| Cash And Equivalents | 127.82 K | |||
| Total Debt | 2.9 M | |||
| Current Ratio | 0.22 X | |||
| Cash Flow From Operations | (5.54 M) | |||
| Short Ratio | 2.60 X | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 16 | |||
| Beta | 22.12 | |||
| Market Capitalization | 20.3 M | |||
| Total Asset | 52 M | |||
| Retained Earnings | (248.68 M) | |||
| Working Capital | 6.84 M | |||
| Current Asset | 18.12 M | |||
| Current Liabilities | 11.29 M | |||
| Z Score | -1.4 |
About Therasense Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Therasense's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Therasense using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Therasense based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Therasense Pink Sheet Analysis
When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.